TY - JOUR
T1 - Association of Infant Antibiotic Exposure With Childhood Health Outcomes
AU - Aversa, Zaira
AU - Atkinson, Elizabeth J.
AU - Schafer, Marissa J.
AU - Theiler, Regan N.
AU - Rocca, Walter A.
AU - Blaser, Martin J.
AU - LeBrasseur, Nathan K.
N1 - Funding Information:
Potential Competing Interests: Dr Rocca has received a grant from the National Institutes of Health ( R01AG034676 ). He is an employee of Mayo Clinic (outside the submitted work). The other authors report no competing interests.
Funding Information:
Grant Support: This study was made possible by the Rochester Epidemiology Project (grant no. R01-AG034676 from the National Institute on Aging ; Principal Investigators: Walter A. Rocca, MD, MPH, and Jennifer L. St Sauver, PhD). This work was supported by the Pritzker Foundation (Dr LeBrasseur) and Leonard and Mary Lou Hoeft Fund in Healthy Aging and Independent Living Research (Dr LeBrasseur). This work was also supported in part by the National Institute of Allergy and Infectious Diseases (U01 AI22285), the C&D fund, and the Fondation Leducq’s Transatlantic Networks of Excellence Program (Dr Blaser). The funding sources for this study did not have a role in the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.
Funding Information:
Grant Support: This study was made possible by the Rochester Epidemiology Project (grant no. R01-AG034676 from the National Institute on Aging; Principal Investigators: Walter A. Rocca, MD, MPH, and Jennifer L. St Sauver, PhD). This work was supported by the Pritzker Foundation (Dr LeBrasseur) and Leonard and Mary Lou Hoeft Fund in Healthy Aging and Independent Living Research (Dr LeBrasseur). This work was also supported in part by the National Institute of Allergy and Infectious Diseases (U01 AI22285), the C&D fund, and the Fondation Leducq's Transatlantic Networks of Excellence Program (Dr Blaser). The funding sources for this study did not have a role in the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.Potential Competing Interests: Dr Rocca has received a grant from the National Institutes of Health (R01AG034676). He is an employee of Mayo Clinic (outside the submitted work). The other authors report no competing interests.
Publisher Copyright:
© 2020 Mayo Foundation for Medical Education and Research
PY - 2021/1
Y1 - 2021/1
N2 - Objective: To investigate the extent to which antibiotic exposure in the first 2 years of life is associated with the risk of immunological, metabolic, and neurobehavioral health conditions with childhood onset. Patients and Methods: In this population-based cohort study, we identified all children born in Olmsted County, Minnesota, between January 1, 2003, and December 31, 2011, through the Rochester Epidemiology Project medical records-linkage system. Demographic characteristics, antibiotic prescriptions, and diagnostic codes through June 30, 2017, were retrieved using the Rochester Epidemiology Project infrastructure. Time-to-event analysis was performed to assess the impact of antibiotic exposure on the risk of several adverse health conditions. Results: This study included 14,572 children (7026 girls and 7546 boys), of whom 70% (10,220) received at least 1 antibiotic prescription during the first 2 years of life. Early antibiotic exposure was associated with an increased risk of childhood-onset asthma, allergic rhinitis, atopic dermatitis, celiac disease, overweight, obesity, and attention deficit hyperactivity disorder (hazard ratios ranging from 1.20 to 2.89; P<.05 for all). The associations were influenced by the number, type, and timing of antibiotic exposure. Moreover, children exposed to antibiotics had a higher probability of having combinations of conditions, particularly when given multiple prescriptions. Conclusion: The present study finds significant associations between early life antibiotic exposure and several distinct health conditions with childhood onset. Additional research is warranted to establish practical guidelines to optimize the benefit and minimize the risk of antibiotics in children.
AB - Objective: To investigate the extent to which antibiotic exposure in the first 2 years of life is associated with the risk of immunological, metabolic, and neurobehavioral health conditions with childhood onset. Patients and Methods: In this population-based cohort study, we identified all children born in Olmsted County, Minnesota, between January 1, 2003, and December 31, 2011, through the Rochester Epidemiology Project medical records-linkage system. Demographic characteristics, antibiotic prescriptions, and diagnostic codes through June 30, 2017, were retrieved using the Rochester Epidemiology Project infrastructure. Time-to-event analysis was performed to assess the impact of antibiotic exposure on the risk of several adverse health conditions. Results: This study included 14,572 children (7026 girls and 7546 boys), of whom 70% (10,220) received at least 1 antibiotic prescription during the first 2 years of life. Early antibiotic exposure was associated with an increased risk of childhood-onset asthma, allergic rhinitis, atopic dermatitis, celiac disease, overweight, obesity, and attention deficit hyperactivity disorder (hazard ratios ranging from 1.20 to 2.89; P<.05 for all). The associations were influenced by the number, type, and timing of antibiotic exposure. Moreover, children exposed to antibiotics had a higher probability of having combinations of conditions, particularly when given multiple prescriptions. Conclusion: The present study finds significant associations between early life antibiotic exposure and several distinct health conditions with childhood onset. Additional research is warranted to establish practical guidelines to optimize the benefit and minimize the risk of antibiotics in children.
UR - http://www.scopus.com/inward/record.url?scp=85097224339&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097224339&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2020.07.019
DO - 10.1016/j.mayocp.2020.07.019
M3 - Article
C2 - 33208243
AN - SCOPUS:85097224339
VL - 96
SP - 66
EP - 77
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
SN - 0025-6196
IS - 1
ER -